LEVEL 38, MELBOURNE, VICTORIA, C3
CEO Connect Presentation
Reports Ryoncil® Net Revenues of US$30.3M and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain
.4
ACQUIRES CHIMERIC ANTIGEN RECEPTOR (CAR) PLATFORM TECHNOLOGY FOR PRECISION-ENHANCED CELL PRODUCTS
Receives IND Clearance from FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil® in Duchenne Muscular Dystrophy
Files New Issue Announcements with the Australian Securities Exchange
CONTINUES SUCCESSFUL FIRST YEAR LAUNCH WITH NET SALES OF US$30.3M IN MARCH QUARTER
Annual and Transition Report of Foreign Private Issuers
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Amended Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
No filings found
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Correspondence
Submission Upload